Instead of presenting its arguments to the district court, Cobalt Pharmaceuticals Inc. (“Cobalt”) stipulated that it would be bound by the district court’s final judgment order in the related ongoing litigation Ortho McNeil Pharmaceutical, Inc. v. Mylan Laboratories Inc., Case No. 04-cv-1689 (SRC) (D.N.J.) (“Ortho v. Mylan”). Accordingly, when the district court entered its judgment permanently enjoining Mylan from infringing Ortho McNeil’s U.S. Patent No. 4,513,006 (’006) covering topira-mate, it also entered final judgment against Cobalt. Cobalt retained its rights to appeal to this court, but stipulated that such an appeal would be based on the record of the Ortho v. Mylan litigation.

For the reasons set forth in the simultaneously issued opinion Ortho McNeil Pharmaceutical, Inc. v. Mylan Laboratories, No.2007-1223, this court affirms the district court’s judgment against Cobalt. Because Cobalt’s argument that claim 1 is rendered indefinite by the inclusion of the phrase “may be” in the second clause that describes R2 and R3 and/or R4 and R5 when they are together was not presented to the district court, and because Cobalt stipulated that its appeal be based on the record in Ortho v. Mylan, this court declines to consider that argument now.

AFFIRMED.